BioVie Presents Protocol Design Of Upcoming SUNRISE-PD Phase 2 Trial Of Bezisterim In Patients With Early Parkinson's Disease At ATMRD 2024
Portfolio Pulse from Benzinga Newsdesk
BioVie Inc. presented the protocol design for its upcoming SUNRISE-PD Phase 2 trial of bezisterim (NE3107) in early Parkinson's disease patients at the ATMRD 2024 Congress. The trial will evaluate the drug's effect on motor and non-motor symptoms in approximately 60 patients. Data from an earlier Phase 2a trial were also highlighted.
June 25, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioVie Inc. presented the protocol design for its upcoming SUNRISE-PD Phase 2 trial of bezisterim in early Parkinson's disease patients at the ATMRD 2024 Congress. The trial will evaluate the drug's effect on motor and non-motor symptoms in approximately 60 patients. Data from an earlier Phase 2a trial were also highlighted.
The announcement of the SUNRISE-PD Phase 2 trial protocol and the presentation of earlier Phase 2a trial data are positive developments for BioVie Inc. These updates could generate investor interest and optimism about the company's progress in developing treatments for Parkinson's disease, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100